- Home
- ACLX vs ALKS Comparison
ACLX vs ALKS Comparison
Compare ACLX & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACLX
- ALKS
- Stock Information
- Founded
- ACLX 2015
- ALKS 1987
- Country
- ACLX United States
- ALKS Ireland
- Employees
- ACLX N/A
- ALKS N/A
- Industry
- ACLX Biotechnology: Pharmaceutical Preparations
- ALKS Biotechnology: Pharmaceutical Preparations
- Sector
- ACLX Health Care
- ALKS Health Care
- Exchange
- ACLX Nasdaq
- ALKS Nasdaq
- Market Cap
- ACLX 4.4B
- ALKS 5.0B
- IPO Year
- ACLX 2022
- ALKS 1991
- Fundamental
- Price
- ACLX $85.09
- ALKS $29.74
- Analyst Decision
- ACLX Strong Buy
- ALKS Strong Buy
- Analyst Count
- ACLX 12
- ALKS 14
- Target Price
- ACLX $113.08
- ALKS $42.21
- AVG Volume (30 Days)
- ACLX 548.8K
- ALKS 2.1M
- Earning Date
- ACLX 11-07-2025
- ALKS 10-28-2025
- Dividend Yield
- ACLX N/A
- ALKS N/A
- EPS Growth
- ACLX N/A
- ALKS 21.99
- EPS
- ACLX N/A
- ALKS 2.08
- Revenue
- ACLX $56,979,000.00
- ALKS $1,505,296,000.00
- Revenue This Year
- ACLX N/A
- ALKS N/A
- Revenue Next Year
- ACLX $210.73
- ALKS $1.59
- P/E Ratio
- ACLX N/A
- ALKS $14.47
- Revenue Growth
- ACLX N/A
- ALKS N/A
- 52 Week Low
- ACLX $47.86
- ALKS $25.17
- 52 Week High
- ACLX $107.37
- ALKS $36.45
- Technical
- Relative Strength Index (RSI)
- ACLX 54.28
- ALKS 46.39
- Support Level
- ACLX $82.64
- ALKS $29.94
- Resistance Level
- ACLX $94.07
- ALKS $32.02
- Average True Range (ATR)
- ACLX 3.64
- ALKS 1.07
- MACD
- ACLX -0.81
- ALKS -0.23
- Stochastic Oscillator
- ACLX 21.43
- ALKS 7.32
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
About ALKS Alkermes plc
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.